Skip to main content

Monoclonal Antibody Deal Benchmarks in Hematology

Median Upfront
$622M
Range: $326M - $911M
Total Deal Value
$3.1B
Range: $1.9B - $4.2B
Royalty Rate
8.6% - 16.2%
Tiered up to 20.2%
Dev Milestones
$515M
Range: $332M - $699M
Model Your Deal

Market Analysis

Monoclonal Antibody therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in hematology is $622M, with total deal values reaching $3.1B. Development milestones average $515M, while regulatory milestones contribute $613M.

The hematology monoclonal antibody landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody hematology deals range from 8.6% to 16.2% at the base tier, with tiered escalation reaching 12.6%-20.2% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody hematology licensing deal?
Based on our analysis, Phase 2 monoclonal antibody licensing deals in hematology average $622M in upfront payments, with a range of $326M to $911M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for monoclonal antibody hematology transactions?
The median total deal value for Phase 2 monoclonal antibody assets in hematology is $3.1B, ranging from $1.9B to $4.2B. This includes development milestones ($515M), regulatory milestones ($613M), and commercial milestones ($1.3B).
What royalty rates are standard for monoclonal antibody deals in hematology?
Base royalty rates for monoclonal antibody hematology transactions range from 8.6% to 16.2%, with tiered escalations reaching 12.6%-20.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in monoclonal antibody hematology deals?
Monoclonal Antibody hematology deals allocate approximately 80% of total deal value to milestones. Development milestones ($515M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($613M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

CAR-T (Hematologic) in Hematology

View

Bispecific Antibody in Hematology

View

Monoclonal Antibody in Oncology

View

Monoclonal Antibody in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included